Multimodality Therapy for Locoregional Nasopharyngeal Carcinoma—A Decision Tool for Treatment Optimization

Abstract

Locoregional nasopharyngeal cancer (NPC) is a heterogeneous disease with variable epidemiological, clinical, and biological characteristics. Radiotherapy (RT) has become the therapeutic backbone of this disease; however, the optimal combined modality therapeutic approach remains an area of controversy. In this setting, National Comprehensive Cancer Network guidelines offer multiple treatment options that include clinical trial enrollment, concurrent systemic therapy and RT followed by adjuvant chemotherapy, induction chemotherapy followed by systemic therapy and RT, or

Targeting EIF3C to suppress the development and progression of nasopharyngeal carcinoma

“…Compared with common squamous cell carcinoma of the head and neck, nasopharyngeal carcinoma has characteristic clinical manifestations, which is sensitive to radiotherapy and chemotherapy, and has a better prognosis. With the emphasis on the development of radiotherapy technology and the optimization of chemotherapy regimen, the local regional control rate of Nasopharyngeal carcinoma has been significantly improved, but there are still 3%–27% patients with treatment failure ( Liao et al, 2020 ; Rosenberg, 2020 ; Huang et al, 2021 ).…”